A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial is a single center, open-label, dose-finding study of recombinant human relaxin (rhRlx) given intravenously (IV) to patients with stable, compensated CHF.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
• Treatments: Methocarbamol

Criteria

Inclusion Criteria:

• Male and female patients over the age of 18

• New York Heart Association (NYHA) Class II-III CHF

• Left Ventricular Ejection Fraction (LVEF) of < 35%

Exclusion Criteria:

• Acute coronary syndrome

• Acute decompensated CHF

• Hypotension

• Recent significant arrhythmia

• Recent stroke

• Significant renal or hepatic impairment

• Pregnancy or child-bearing potential